AU2007322291A1 - Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof - Google Patents

Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof

Info

Publication number
AU2007322291A1
AU2007322291A1 AU2007322291A AU2007322291A AU2007322291A1 AU 2007322291 A1 AU2007322291 A1 AU 2007322291A1 AU 2007322291 A AU2007322291 A AU 2007322291A AU 2007322291 A AU2007322291 A AU 2007322291A AU 2007322291 A1 AU2007322291 A1 AU 2007322291A1
Authority
AU
Australia
Prior art keywords
antiarrhythmics
omega
treatment
fatty acids
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007322291A
Other languages
English (en)
Inventor
George Bobotas
Abdel A. Fawzy
Roelof M.L. Rongen
Ihor Terleckyj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of AU2007322291A1 publication Critical patent/AU2007322291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2007322291A 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof Abandoned AU2007322291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85129406P 2006-10-13 2006-10-13
US60/851,294 2006-10-13
PCT/US2007/021963 WO2008063323A2 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof

Publications (1)

Publication Number Publication Date
AU2007322291A1 true AU2007322291A1 (en) 2008-05-29

Family

ID=39430253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007322291A Abandoned AU2007322291A1 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof

Country Status (10)

Country Link
EP (1) EP2083802A2 (ko)
JP (1) JP2010506841A (ko)
KR (1) KR20090086078A (ko)
CN (1) CN101557805A (ko)
AU (1) AU2007322291A1 (ko)
BR (1) BRPI0719183A2 (ko)
CA (1) CA2672876A1 (ko)
EA (1) EA200970374A1 (ko)
MX (1) MX2009003928A (ko)
WO (1) WO2008063323A2 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
JP5563573B2 (ja) * 2008-08-07 2014-07-30 エッセピア ソシエタ’ プロドッティ アンティビオティチ ソシエタ ペル アチオニ 症候性心不全の長期治療
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011876B1 (pt) * 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
CN102188417A (zh) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 决奈达隆药物组合物
FR2967067A1 (fr) 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
EP2755646A4 (en) * 2011-09-15 2015-06-10 Omthera Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO THROMBIA THERAPY
WO2013116738A1 (en) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Drug formulations
AU2013264518B2 (en) 2012-05-22 2016-02-11 Kuhnil Pharm. Co., Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
WO2017083397A1 (en) * 2015-11-09 2017-05-18 Cayo Max A Cardiac glycosides for the treatment of hypercholesterolemia
WO2017139757A1 (en) * 2016-02-12 2017-08-17 The General Hospital Corporation Targeting macrophages to modulate electrical conduction in the heart
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2019204326A1 (en) * 2018-04-16 2019-10-24 Alsar Ltd Partnership Compositions and methods for sustained release of flecainide
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB0120415D0 (en) * 2001-08-22 2001-10-17 Isis Innovation Palatable high fat composition
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3

Also Published As

Publication number Publication date
MX2009003928A (es) 2009-09-21
WO2008063323A2 (en) 2008-05-29
CA2672876A1 (en) 2008-05-29
EP2083802A2 (en) 2009-08-05
JP2010506841A (ja) 2010-03-04
CN101557805A (zh) 2009-10-14
KR20090086078A (ko) 2009-08-10
WO2008063323A3 (en) 2008-12-31
EA200970374A1 (ru) 2009-10-30
BRPI0719183A2 (pt) 2014-06-03

Similar Documents

Publication Publication Date Title
AU2007322291A1 (en) Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
EP1861087A4 (en) TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
EP1919468A4 (en) TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
EP1903883A4 (en) OIL PRODUCT CONTAINING MULTIPLE UNSATURATED FATTY ACIDS AND ITS USES AND MANUFACTURING
EP2007215A4 (en) FOODSTUFFS WITH LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THE PRODUCTION THEREOF
AU2016202449A1 (en) Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
HK1132433A1 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
ZA201003030B (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
SI2408426T1 (sl) Oftalmični sestavki na osnovi polinenasičenih omega-3 in omega-6 maščobnih kislin
EP2173699A4 (en) PRODUCTION AND PURIFICATION OF POLYUNSATURATED FATTY ACID ESTERS
EP2046957A4 (en) DATURURASES OF FATTY ACIDS AND USES THEREOF
GB2444896B (en) Compositions comprising polyunsaturated fatty acids
ZA200808635B (en) Food supplements and uses thereof
PL2214638T3 (pl) Kompozycja zawierająca wielonienasycone kwasy tłuszczowe i węgiel aktywny
EP1991594A4 (en) HYBRID POLYMER OF ACRYLATE BASED ON NATURAL FATTY ACIDS AND METHOD OF MAKING SAME
EP2114397A4 (en) NOVEL CONJUGATES OF POLY-UNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF
PL2376638T3 (pl) Desaturazy oraz sposób wytwarzania wielonienasyconych kwasów tłuszczowych w organizmach transgenicznych
PL2390339T3 (pl) Delta-8 desaturazy i ich zastosowanie w wytwarzaniu polinienasyconych kwasów tłuszczowych
SI2034999T1 (sl) DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni
EP1991617A4 (en) COMPOSITE MATERIAL, CONTAINING MODIFIED HYBRID RESIN BASED ON NATURAL FATTY ACIDS
EP2317873A4 (en) FRUIT PRODUCTS CONTAINING OMEGA-3 FATTY ACIDS
HK1124732A1 (en) The nuts topping biscuit process which is stable in oxidation
EP2094242A4 (en) IN A MATRIX EMBEDDED COMPOSITIONS WITH ORGANIC ACIDS AND FATTY ACIDS
WO2008068413A3 (fr) Procede de preparation d'acetyl, docosahexaenoyl-glycérophosphocholine, et son utilisation pour l'apport d'acides gras polyinsatures
EP2077822A4 (en) ORAL FORMULATION CONTAINING OXCARBAZEPINE AND METHOD FOR PRODUCING THE SAME

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period